Schering-Plough announced FDA approval on a key pipeline antipsychotic today, and is building a US sales force for the Q4 launch. The product, Saphris (asenapine), received approval on two indications ...

allergan The labeling for Saphris (asenapine; Allergan) sublingual tablets has been updated with an expanded bipolar I disorder indication, dosage modifications, and a new contraindication. The ...

Pharmaceutical company Forest Laboratories (FRX) announced plans on Monday to streamline operations in a bid to save money, while also saying that it is aiming to bolster sales by buying the U.S.

Saphris Actavis announced that the Food and Drug Administration (FDA) has approved Saphris (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I ...

No patients treated with SAPHRIS experienced QTc increases of equal to or greater than 60 msec from baseline measurements, nor did any experience a QTc of equal to or greater than 500 msec. SAPHRIS ...

Please provide your email address to receive an email when new articles are posted on . Results from a randomized trial indicate Saphris was effective and well-tolerated among adolescents with bipolar ...

WASHINGTON, Aug. 14 (UPI) -- Schering-Plough Corp.'s asenapine has been cleared for sale as a treatment for schizophrenia and bipolar disorder in adults, U.S. authorities said. The drug is to be made ...

Positive news flowed in at Actavis plc ACT with the FDA approving its supplemental new drug application for Saphris as a monotherapy for acute manic or mixed episodes associated with bipolar I ...

The US Food and Drug Administration (FDA) has approved another atypical antipsychotic for the treatment of pediatric patients with bipolar I disorder. According to a release issued by the drug's ...

(MENAFN- IMARC Group) IMARC Group's report, titled “Asenapine (Saphris) Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost ...

Schering-Plough surprised analysts with optimistic news from the U.S. Food and Drug Administration about a schizophrenia drug candidate. The regulatory agency sent a letter to the pharmaceutical ...